Breast Imaging Market is sophistication of Technologies Set to Expand Upcoming Years

Pune, India, May 2019, MRFR Press Release/- Market Research Future has Published a Half-Cooked Research Report on the Global Breast Imaging Market.

Market Synopsis

Rising prevalence of tumors and cancers among the women is encouraging the development of a market for dealing with the issues faced by them. The increasing population of females in conjunction with rising healthcare expenditures is expected to unleash developmental opportunities to the markets dealing with the health disorders found in women. Market Research Future (MRFR) has published a study on the global breast imaging market to assess its prospects. The analysis reveals that the market is projected to exhibit a CAGR of 8.3% during the review period 2023 to 2032.

Breast cancer is one of the widely present cancers with a high fatality rate. Around 200,000 new cases are registered every year, as per stated by the World Health Organization (WHO). This has encouraged the leaders in the healthcare industry to research & develop advanced devices focused on women health. It is projected to motivate the growth trends in the breast imaging market over the next few years.

Breast imaging is gaining traction for the assessment of tumors. Women are getting increasingly aware of the health disorders which has generated demand for early detection of diseases. It is expected to revolutionize the growth trajectory of the global breast imaging market in the years to come. However, the stigma associated with these diseases in developing nations restricts women from accessing medical facilities. This, in turn, is anticipated to undermine market growth over the next few years.

Market Segmentation

By type, the global breast imaging market has been segmented into mammography, PET, CT, MRI, breast biopsy, ultrasound, tactile imaging, and others. The mammography segment is further sub-segmented into film-screen mammography, 3D mammography, Full-field digital mammography (FFDM), scintimammography or molecular breast imaging, and others. The breast biopsy has been sub-segmented into image-guided breast biopsy, ultrasound-guided core biopsy, tactic core biopsy, and others.

Based on application, the breast imaging market has been segmented into breast cancer diagnosis, metastatic axillary adenocarcinoma, post-neoadjuvant chemotherapy, and others.

The breast imaging market, by end user, has been segmented into diagnostic centers, hospitals, and others.

Competitive Dashboard

The key players participating in the share analysis of the global breast imaging market are General Electric Company (U.K.), Koninklijke Philips N.V. (Netherlands), Siemens (Germany), Hologic, Inc. (U.S.), Dilon Technologies, Inc. (U.S.), Fujifilm Holdings Corporation (Japan), Aurora Imaging Technology, Inc. (U.S.), Toshiba Corporation (Japan), Gamma Medica, Inc. (U.S.), and Sonocine, Inc. (U.S.).

Explore In-depth Market Details [Table of Content, List of Figures, List of Tables] of Breast Imaging Market Research Report

Regional Analysis

By region, the global breast imaging market has been segmented into Americas, Asia Pacific, Europe, and the Middle East & Africa (MEA). Americas is the largest market for breast imaging. The region is burdened with the rising patient population of breast cancer. On the other hand, the technological advancements in the healthcare sector of the region are skyrocketing. Thus, a healthy growth trajectory has been forecasted for the breast imaging market in the region.

Asia Pacific is witnessing developments in healthcare technology, which is expected to augment breast imaging market in the region. The economic development in the region is likely to have a positive influence on the growth trends of the market in the forthcoming years.

Industry News

• In January 2019, QTbreasthealth, an advanced imaging center, has announced the launch of a New Breast Ultrasound Imaging Center in Grand Rapids, Mich., featuring its QTscan quantitative transmission ultrasound technology.

• In October 2018, Royal Philips, a Dutch multinational technology company headquartered in Amsterdam, has introduced its latest all-in-one breast imaging solution to be used with use with its Epiq and Affiniti ultrasound systems.

• In July 2018, The U.S. Food and Drug Administration announced the approval for a magnetic device system to guide lymph node biopsies in patients who are suffering from breast cancer and undergoing mastectomy.